Petros Pharmaceuticals, Inc. Employee Benefit and Share-based Payment Arrangement, Noncash
Petros Pharmaceuticals, Inc. (PTPI) reported Employee Benefit and Share-based Payment Arrangement, Noncash of $229.50 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash · last filed 2025-11-13
- Petros Pharmaceuticals, Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2025-09-30 was $75.14K.
- Petros Pharmaceuticals, Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2025-06-30 was $74.32K, a 341.49% increase year-over-year.
- Petros Pharmaceuticals, Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2025-03-31 was $80.04K, a 55.63% decline year-over-year.
- Petros Pharmaceuticals, Inc. employee benefit and share-based payment arrangement, noncash for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Petros Pharmaceuticals, Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2024 was $197.22K, a 52.73% decline from fiscal 2023.
- Petros Pharmaceuticals, Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2023 was $417.23K, a 65.09% decline from fiscal 2022.
- Petros Pharmaceuticals, Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2022 was $1.20M, a 6.96% increase from fiscal 2021.
- Petros Pharmaceuticals, Inc. employee benefit and share-based payment arrangement, noncash for fiscal 2021 was $1.12M.
| Period end | Employee Benefit and Share-based Payment Arrangement, Noncash 3 month | Employee Benefit and Share-based Payment Arrangement, Noncash 6 month | Employee Benefit and Share-based Payment Arrangement, Noncash 9 month | Employee Benefit and Share-based Payment Arrangement, Noncash 12 month |
|---|---|---|---|---|
| 2025-09-30 | $75.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $149.46K derived: sum of 2 quarters · filed 2025-11-13 | $229.50K 10-Q · filed 2025-11-13 | $229.50K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | $74.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $154.36K 10-Q · filed 2025-08-14 | $154.36K derived: sum of 3 quarters · filed 2025-08-14 | $154.36K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | $80.04K 10-Q · filed 2025-05-15 | $80.04K derived: sum of 2 quarters · filed 2025-05-15 | $80.04K derived: sum of 3 quarters · filed 2025-11-13 | $96.87K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $16.83K derived: sum of 3 quarters · filed 2025-11-13 | $197.22K 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $16.83K derived: sum of 2 quarters · filed 2025-11-13 | $197.22K 10-Q · filed 2025-11-13 | $409.95K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $16.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $197.22K 10-Q · filed 2025-08-14 | $409.95K derived: sum of 3 quarters · filed 2025-08-14 | $440.79K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $180.38K 10-Q · filed 2025-05-15 | $393.12K derived: sum of 2 quarters · filed 2025-05-15 | $423.96K derived: sum of 3 quarters · filed 2025-05-15 | $467.27K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $212.74K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $243.58K derived: sum of 2 quarters · filed 2025-03-31 | $286.89K derived: sum of 3 quarters · filed 2025-03-31 | $417.23K 10-K · filed 2025-03-31 |
| 2023-09-30 | $30.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $74.16K derived: sum of 2 quarters · filed 2024-11-13 | $204.49K 10-Q · filed 2024-11-13 | $433.34K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $43.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $173.65K 10-Q · filed 2024-08-14 | $402.50K derived: sum of 3 quarters · filed 2024-08-14 | $710.63K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $130.34K 10-Q · filed 2024-05-15 | $359.18K derived: sum of 2 quarters · filed 2024-05-15 | $667.32K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $228.84K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $536.98K derived: sum of 2 quarters · filed 2024-04-01 | $1.20M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $308.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | $966.23K 10-Q · filed 2023-11-15 | ||
| 2022-06-30 | $658.09K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $126.47K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $1.12M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $990.88K 10-Q/A · filed 2022-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |